Literature DB >> 29766874

Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry.

Amit Noheria1, Peter Shrader2, Jonathan P Piccini2, Gregg C Fonarow3, Peter R Kowey4, Kenneth W Mahaffey5, Gerald Naccarelli6, Peter A Noseworthy7, James A Reiffel8, Benjamin A Steinberg2, Laine E Thomas2, Eric D Peterson2, Bernard J Gersh9.   

Abstract

OBJECTIVES: The study sought to evaluate clinical outcomes in clinical practice with rhythm control versus rate control strategy for management of atrial fibrillation (AF).
BACKGROUND: Randomized trials have not demonstrated significant differences in stroke, heart failure, or mortality between rhythm and rate control strategies. The comparative outcomes in contemporary clinical practice are not well described.
METHODS: Patients managed with a rhythm control strategy targeting maintenance of sinus rhythm were retrospectively compared with a strategy of rate control alone in a AF registry across various U.S. practice settings. Unadjusted and adjusted (inverse-propensity weighted) outcomes were estimated.
RESULTS: The overall study population (N = 6,988) had a median of 74 (65 to 81) years of age, 56% were males, 77% had first detected or paroxysmal AF, and 68% had CHADS2 score ≥2. In unadjusted analyses, rhythm control was associated with lower all-cause death, cardiovascular death, first stroke/non-central nervous system systemic embolization/transient ischemic attack, or first major bleeding event (all p < 0.05); no difference in new onset heart failure (p = 0.28); and more frequent cardiovascular hospitalizations (p = 0.0006). There was no difference in the incidence of pacemaker, defibrillator, or cardiac resynchronization device implantations (p = 0.99). In adjusted analyses, there were no statistical differences in clinical outcomes between rhythm control and rate control treated patients (all p > 0.05); however, rhythm control was associated with more cardiovascular hospitalizations (hazard ratio: 1.24; 95% confidence interval: 1.10 to 1.39; p = 0.0003).
CONCLUSIONS: Among patients with AF, rhythm control was not superior to rate control strategy for outcomes of stroke, heart failure, or mortality, but was associated with more cardiovascular hospitalizations.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antiarrhythmic drugs; atrial fibrillation; rate control; rhythm control

Year:  2015        PMID: 29766874     DOI: 10.1016/j.jacep.2015.11.001

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  9 in total

1.  Rhythm Control Vs Rate Control in a Contemporary Ambulatory Atrial Fibrillation Cohort: Post Hoc Analysis of the IMPACT-AF Trial.

Authors:  Arun Govindapillai; Jafna L Cox; Lehana Thabane; Steve Doucette; Feng Xie; James H MacKillop; Antonio Ciaccia; Shurjeel H Choudhri; Joanna M Nemis-White; Laura M Hamilton; Ratika Parkash
Journal:  CJC Open       Date:  2022-03-08

2.  Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Authors:  Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara
Journal:  Intern Emerg Med       Date:  2021-12-02       Impact factor: 5.472

Review 3.  Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis.

Authors:  Laurence Depoorter; Liza Sels; Mieke Deschodt; Bastiaan Van Grootven; Lorenz Van der Linden; Jos Tournoy
Journal:  Drugs Aging       Date:  2020-01       Impact factor: 3.923

4.  Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation.

Authors:  J'Neka S Claxton; Alanna M Chamberlain; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Lindsay G S Bengtson; Alvaro Alonso
Journal:  Am J Med       Date:  2020-04-19       Impact factor: 4.965

5.  Comparative occurrence of ischemic stroke with the rhythm versus rate control strategy in a national prospective cohort of atrial fibrillation.

Authors:  Jae Guk Kim; Young Soo Lee; Ki-Woon Kang; Eue-Keun Choi; Myung-Jin Cha; Jung-Myung Lee; Jin-Bae Kim; Junbeom Park; Jin-Kyu Park; Tae-Hoon Kim; Jae-Sun Uhm; Jaemin Shim; Jun Kim; HyungWook Park; Changsoo Kim; Boyoung Joung
Journal:  Korean J Intern Med       Date:  2019-10-14       Impact factor: 2.884

6.  Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database.

Authors:  Vinita Subramanya; J'Neka S Claxton; Pamela L Lutsey; Richard F MacLehose; Lin Y Chen; Alanna M Chamberlain; Faye L Norby; Alvaro Alonso
Journal:  BMC Cardiovasc Disord       Date:  2021-12-16       Impact factor: 2.298

7.  Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry.

Authors:  Giuseppe Boriani; Gregory Y H Lip; Marco Proietti; Marco Vitolo; Stephanie L Harrison; Deirdre A Lane; Laurent Fauchier; Francisco Marin; Michael Nabauer; Tatjana S Potpara; Gheorghe-Andrei Dan
Journal:  Clin Res Cardiol       Date:  2021-08-27       Impact factor: 5.460

8.  Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study.

Authors:  Rachel S Kim; Steven Simon; Brett Powers; Amneet Sandhu; Jose Sanchez; Ryan T Borne; Alexis Tumolo; Matthew Zipse; J Jason West; Ryan Aleong; Wendy Tzou; Michael A Rosenberg
Journal:  JMIR Med Inform       Date:  2021-12-06

9.  Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.

Authors:  Andreas Metzner; Anna Suling; Axel Brandes; Günter Breithardt; A John Camm; Harry J G M Crijns; Lars Eckardt; Arif Elvan; Andreas Goette; Laurent M Haegeli; Hein Heidbuchel; Josef Kautzner; Karl-Heinz Kuck; Luis Mont; G Andre Ng; Lukasz Szumowski; Sakis Themistoclakis; Isabelle C van Gelder; Panos Vardas; Karl Wegscheider; Stephan Willems; Paulus Kirchhof
Journal:  Europace       Date:  2022-04-05       Impact factor: 5.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.